SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending due to the commercial launch of TONMYA, a first-in-class fibromyalgia treatment, sparking discussions about its market potential and insurance coverage. While some express concerns over past dilutions and future profitability, others highlight the company's cash runway and potential for a squeeze. The community is closely watching for sales data and confirmation of distribution milestones as key catalysts for price movement.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to recent earnings report indicating a 50% YoY revenue increase and record customer growth, although margins were pressured by higher delivery expenses. Community discussion revolves around the impressive revenue numbers and store expansion, with some expressing concern over margin decline and a lack of updates regarding a potential US relisting. Overall, while growth is undeniable, the sustainability of margins and potential catalysts like relisting are key talking points.

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Zymeworks BC Inc

Zymeworks Inc

ZYME is trending following positive Phase 3 trial results for their cancer treatment Ziihera, developed in partnership with Jazz Pharmaceuticals. The community is discussing the potential impact on HER2-positive cancers and the financial implications for both ZYME and Jazz. Some traders caution about low trading volume and the potential risks of getting in now.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending after Berkshire Hathaway disclosed a $4.3 billion stake, fueling optimism and driving shares up. The community is discussing whether this move signals a broader shift in Warren Buffett's investment strategy towards tech and AI, while others debate the valuation and potential for further gains. This news coincides with Alphabet's ongoing investments in data centers to support cloud and AI initiatives.

Grindr, Inc. engages in the operation of a social media network application for the gay, bi, trans, queer, and other members of the LGBTQ+ community. The company was founded in 2009 and is headquartered in West Hollywood, CA.

Grindr Inc - Ordinary Shares - Class A

Grindr Inc

Grindr is trending amid buyout speculation, with community members debating the likelihood of a deal and potential premium. Discussions also involve insider selling and its impact on a possible acquisition. Despite the uncertainty, some believe GRND is undervalued, citing strong earnings and analyst price targets.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet (STRK) is trending due to a surge in staking and BTCFi incentives, with the community noting a strong weekly breakout and increased bullish sentiment. Discussions highlight the potential of Starknet's technology, particularly its zero-knowledge proof system, and its growing ecosystem, with some viewing it as a key player in the future of decentralized finance. Comparisons to Zcash ($ZEC) are also circulating, emphasizing the privacy aspects of Starknet.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium ($SGML) is trending amid discussions around lithium prices, production capacity, and potential takeover scenarios. Community members are analyzing the impact of fluctuating lithium prices on the company's future earnings and debating whether recent price movements signal a potential sector recovery, while also noting insider buying activity. Some traders discuss technical indicators and potential short squeezes, while cautioning of continued volatility given recent price action.

Meme coin community on Aurora focuses on promoting the NEAR eco and fostering camaraderie and promotions of member's content creation.

Shitzu

Shitzu is trending heavily as traders actively discuss the cryptocurrency. Increased social media mentions suggest growing interest and speculative trading, though the specific catalyst for the surge in attention remains unclear. The community is focused on the potential of this relatively new and volatile cryptocurrency.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending due to positive developments in AI and robotics, including the unveiling of its 'Iron' humanoid robot, and expansion into new European markets. Community discussions revolve around the company's potential to surpass Tesla in robotics and its attractive valuation relative to its growth and innovation. Upcoming earnings are also a key point of interest, with investors anticipating strong results.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

Wasatch Pharmaceutical Inc

Wasatch Pharmaceutical ($WSHP) is trending due to its recent direct listing, with the community actively discussing its volatile price action and potential trading opportunities. Some traders are highlighting the stock's significant move post-listing, while others are cautious, pointing to potential risks. Chatter suggests possible upcoming news related to the company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chiron Capital Management LLC Increases Position in Merck & Co., Inc. $MRK

Chiron Capital Management LLC increased its position in Merck & Co., Inc. (NYSE:MRK - Free Report) by 62.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with...

Avantax Advisory Services Inc. Buys 34,861 Shares of Merck & Co., Inc. $MRK

Avantax Advisory Services Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 15.2% during the second quarter, according to its most recent filing with the Securities and...

<ul class="summary-bullets"><li>Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.</li><li>Major brokerages moved to neutral stances following the announcement.</li><li>Retail traders reacted on Stocktwits, with many celebrating long-held gains.</li></ul><p>Cidara Therapeutics, up more than 700% this year, more than doubled on Friday after Merck unveiled a $9.2 billion all-cash takeover, only for major Wall Street firms to turn neutral on the biotech following the deal’s announcement.</p><p>The deal values Cidara at $221.50 per share, representing a roughly 109% premium to Thursday’s close, and is expected to close in the first quarter of 2026, subject to customary conditions.</p><h2 class="st-heading-2"><strong>Analysts Cut Ratings After Deal Announcement</strong></h2><p>Despite the stock surge, major brokerages shifted to neutral stances across the board. Morgan Stanley downgraded Cidara to ‘Equal Weight’, JPMorgan moved to ‘Neutral’, RBC Capital to ‘Sector Perform’, and Needham shifted to ‘Hold’. H.C. Wainwright also stepped back to ‘Neutral’.&nbsp;</p><h2 class="st-heading-2"><strong>Merck’s Strategic Push Ahead Of Keytruda Patent Expiry</strong></h2><p>Merck said&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-to-buy-cidara-in-9.2-billion-dollar-deal/cLPQJxLRE44">the takeover</a> strengthens its respiratory pipeline ahead of the anticipated 2028 patent loss for Keytruda, its top-selling cancer therapy that generated more than $25 billion last year. The move follows Merck’s $10 billion acquisition of Verona Pharma in July, part of a series of large deals aimed at building future revenue streams.</p><p>Cidara brings Merck its lead candidate, CD388, a long-acting antibody designed to prevent influenza infection in high-risk individuals. The U.S. Food and Drug Administration has granted CD388 Breakthrough Therapy designation, potentially speeding its review. The program is currently in late-stage studies across high-risk populations, including immunosuppressed patients who cannot receive seasonal flu vaccines and adults aged 65 and older. More than 6,000 participants are expected to be enrolled globally by the end of the month.</p><h2 class="st-heading-2"><strong>Competitive Bidding And Rising Value</strong></h2><p>Discussions&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-stock-soars-42-after-hours-on-merck-buyout-buzz/cLPfvfZREEh">reportedly</a> extended late into Thursday as Merck faced competition from another pharmaceutical group before its winning bid was selected. The high demand reflects growing interest in long-acting influenza prevention technologies, particularly for vulnerable populations.</p><p><a href="https://stocktwits.com/symbol/CDTX">Cidara</a> has been among the sector’s strongest performers in recent months. Its shares have been fueled by robust clinical data, speculation about a potential auction, and rising interest in CD388’s commercial prospects. The frenzy comes amid a broader wave of pharmaceutical dealmaking, including Pfizer’s recent win over Novo Nordisk in the race for obesity-drug developer Metsera in a deal worth up to $10 billion.</p><h2 class="st-heading-2"><strong>Stocktwits Users Celebrate Big Payday</strong></h2><p>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both seeing elevated message activity ranging from ‘extremely high’ to ‘high’.</p><p>Some users said they had waited a long time for this outcome and thanked the Cidara team as they exited their positions, while others congratulated holders, noting that the deal delivered major gains for many investors.</p><p><stembedurl>https://stocktwits.com/Tauro83/message/636302166</stembedurl></p><p><stembedurl>https://stocktwits.com/Kabita84/message/636294520</stembedurl></p><p><a href="https://stocktwits.com/symbol/MRK">Merck’s stock</a> has declined 4% so far in 2025.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover 

Merck’s all-cash agreement grants it access to Cidara’s lead flu-prevention antibody, CD388, which has received FDA Breakthrough Therapy designation and is currently in late-stage studies enrolling more than 6,000 participants.

Equity

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Cidara Therapeutics, Inc. (NasdaqCM: CDTX) to...

Westpac Banking Corp Acquires 3,253 Shares of Merck & Co., Inc. $MRK

Westpac Banking Corp lifted its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...

Thoroughbred Financial Services LLC Has $1.31 Million Holdings in Merck & Co., Inc. $MRK

Thoroughbred Financial Services LLC lessened its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 38.7% in the second quarter, according to its most recent disclosure with the...

WealthShield Partners LLC Lowers Stake in Merck & Co., Inc. $MRK

WealthShield Partners LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 87.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities...

Merck & Co., Inc. $MRK Shares Bought by Generali Investments Management Co LLC

Generali Investments Management Co LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 30.5% during the 2nd quarter, according to its most recent Form 13F filing with the...

Persistent Asset Partners Ltd Makes New $368,000 Investment in Merck & Co., Inc. $MRK

Persistent Asset Partners Ltd bought a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor...

Thomas Story & Son LLC Takes Position in Merck & Co., Inc. $MRK

Thomas Story & Son LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and...

🚨 LIVE Earnings on Polymarket. 
Trading earnings just got much simpler: Will your favorite stock beat earnings – Yes or No?

Polymarket

Merck & Co Inc

M&A Announcement

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$93.26
Prev Close	$92.93
Open	$92.20
Dividend Yield	3.14%
50-Day Moving Average	$85.24
Beta	0.29
Avg. Volume	11.41M
PE Ratio	12.29

52-Week High	$105.07
52-Week Low	$73.31
Market Capitalization	$328.36B
EPS (Annual)	$6.74
Price to Book	4.46
Revenue Per Employee	$852,973.33
Enterprise Value/EBITDA	N/A

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc